September 21, 2009 - LifeVest Prescribed at All Top U.S. Hospitals


A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637


September 21, 2009CHELMSFORD, Mass.—ZOLL Medical Corporation (NASDAQ GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that physicians at all of the 21 “Honor Roll” hospitals and all of the 50 “Best Heart and Heart Surgery” hospitals designated by U.S. News and World Report for 2009-2010 have prescribed the ZOLL LifeVest® Wearable Defibrillator for patients.

The LifeVest is worn by patients at risk of sudden cardiac arrest (SCA), allowing their physicians time to assess their long-term arrhythmic risk and make appropriate plans.  The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest does not require bystander intervention and has a 98 percent first treatment shock success rate for resuscitating patients with SCA.

“The LifeVest offers patients the potential for protection from SCA in the highest risk period immediately following a myocardial infarction when other therapies are not indicated due to a patient’s temporary or changing condition,” said Dr. Ranjit Suri, Director of Electrophysiology Service and Cardiac Arrhythmia Center at Lenox Hill Heart and Vascular Institute of New York, which was named to the 50 Best Heart and Heart Surgery hospital list.  “The LifeVest is an important part of the continuum of care to protect our patients at risk of SCA.”

"We believe the continued prescription of the LifeVest in each of the nation’s premier hospitals demonstrates that the LifeVest is developing as a standard of care for patients with a temporary risk of sudden cardiac death,”  said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL.

The LifeVest may be prescribed for patients following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk. It may also be prescribed for patients whose comorbidities, including infections caused by placement of ICDs, prevent them undergoing immediate implant surgery for an ICD.  To date, the LifeVest has been prescribed to more than 18,000 patients.

The LifeVest is rented to patients like other durable medical equipment (DME), allowing physicians to provide the patient the protection of the LifeVest by placing a medical order directly with ZOLL.  The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.  For more information, visit

U.S. News and World Report's "America’s Best Hospitals,” an annual ranking of the country’s elite medical centers, looks at how well a hospital handles complex and demanding situations. A total of 4,861 hospitals were considered; only 174 were ranked in one or more of the 16 specialties, of those, only 21 qualified for the “Honor Roll” designation by earning high scores in at least six specialties.  U.S. News and World Report also named the 50 “Best Heart and Heart Surgery” hospitals in the 2009-2010 report based on rankings within the specific category.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation and temperature control therapies for the treatment of critical care patients. With products for pacing, defibrillation, circulation, temperature management, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, which help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the Company’s resuscitation product development. For more information, visit

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, CodeNet, LifeVest, Real CPR Help, RescueNet, See-Thru CPR, and Thermogard XP are registered trademarks of ZOLL Medical Corporation.